Senescence Life Sciences uses the world’s most advanced breakthroughs in neuroscience to combat brain ageing.
"Our mission is to redefine cognitive health by empowering people to achieve optimal mental agility at work, at home and in their communities," says Dr. Shawn Watson, Founder and Chief Executive Officer, Senescence Life Sciences. "We recognize the worries and implications that come with age-related cognitive decline. This is why we invest in research and development to advance sciences that can help people better cope with brain ageing."
Senescence Life Sciences applies the latest research in age-related cognitive decline to develop scientifically supported supplements that contain neuroprotective compounds extracted from natural ingredients to combat brain ageing. They also aim to break the stigma of ageing by cultivating a mindset where people can look forward to growing older and living life to the fullest.
Dr. Watson, 32, founded the startup with his wife, Tegan. He came to Singapore to start an entirely different job in 2013 with her. Within the first six months of relocating, they were approached by a number of investors in Singapore who were familiar with Dr. Watson's publications and research.
At the time, his research had just started to take off, and a number of labs from around the world were performing observational studies based on his treatment strategy and not only corroborated his results but also showed that a similar mechanism was capable of arresting the progression of Alzheimer’s disease in animal models. "With the exciting prospect that my research could have a huge impact on brain health, we took the jump and Tegan started to work on our business plan and pitch," says Dr. Watson.
All the active ingredients found in their products have reported consistent positive results to improve cognitive performance and protect the brain against natural ageing in at least five clinical trials, says Dr. Watson. The products have also received third-party accreditations of the highest quality testing process. Each batch undergoes at least three rounds of quality testing before it reaches consumers, Dr. Watson shares.
"With a thorough understanding of how the brain ages and functions, we have developed two product lines intended for two different age groups – EDGE for those between 30 and 55 and REVIVE for those above the age of 55," says Dr. Watson. He shares that their products allow customers to experience better sleep, improved learning/memory and increased energy levels. Importantly, he notes, the products are not a stimulant, but target the underlying mechanisms of cognitive decline.
"However, we want to do more than supplements. It is important that we take a proactive approach to raise the awareness of age-related cognitive decline such as symptoms, diet and lifestyle changes and early action to protect ourselves," he says.
At present, the company is actively looking for distributors around ASEAN and East Asia to help bring their products to market. They are also in discussions with several institutions and organisations on potential collaborations for research and clinical trials around their products’ efficacy in slowing down age-related cognitive decline and relief of dementia symptoms.
Do you know more about this story? Contact us anonymously through this link.